| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRANSPROCEED.2011.12.006 |
| P698 | PubMed publication ID | 22310610 |
| P2093 | author name string | Y S Kim | |
| H G Kim | |||
| B S Choi | |||
| C W Yang | |||
| H S Park | |||
| Y A Hong | |||
| C W Park | |||
| B H Chung | |||
| S R Choi | |||
| I O Sun | |||
| P2860 | cites work | A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 |
| Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. | Q37367683 | ||
| C4d-positive chronic rejection: a frequent entity with a poor outcome. | Q51722871 | ||
| Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. | Q53388181 | ||
| Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') | Q79921621 | ||
| Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients | Q82588311 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| rituximab | Q412323 | ||
| P304 | page(s) | 182-184 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. | |
| P478 | volume | 44 |
| Q38215262 | Acute and chronic antibody-mediated rejection in pediatric kidney transplantation |
| Q41758257 | Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. |
| Q35829453 | Increased circulating follicular helper T cells with decreased programmed death-1 in chronic renal allograft rejection. |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q40149564 | Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. |
| Q26826880 | Monoclonal antibody therapy and renal transplantation: focus on adverse effects |
| Q92488629 | Rituximab in kidney disease and transplant |
| Q57474736 | Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection |
| Q40523283 | Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab |
| Q37704938 | The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. |
| Q65000602 | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection. |
| Q58754949 | Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results |
Search more.